Welcome : Guest

BOTULINUM TOXIN - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 15 companies including many key and niche players such as -

Allergan Plc
Ipsen Group
Medy-Tox Inc.
Merz Pharma GmbH & Co. KGaA
Metabiologics, Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-1833
Price: $4950
Companies: 15
Pages: 184
Date: September 2016
Market Data Tables: 57
 



TABLE OF CONTENTS


  BOTULINUM TOXIN (Complete Report) Pages : 184   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth.....II-11$100
   Developed Regions Dominate Botulinum Toxin Market.....II-21$100
   Developing Markets to Drive Future Growth.....II-3 1$100
   Table 1: Healthcare Spending as % of GDP by Geographic Region (2016E) (includes corresponding Graph/Chart).....II-41$350
   Table 2: Top Countries with the Highest Per Capita Healthcare Spending (2014) (includes corresponding Graph/Chart).....II-5
Cosmetic BTX – A Promising Application Market.....II-5
1$350
   Factors Propelling the Cosmetic BT Market – In a Nut Shell.....II-61$100
   Rise in the Number of Musculoskeletal Indications – An Opportunity Indicator.....II-71$100
   Pharma Companies Keenly Eye Lucrative BT Market.....II-81$100
   Allergan Leads the Global BTX Market.....II-9
Table 3: Leading Brands in the Global Botulinum Toxin Market (2015): Percentage Breakdown of mSales for Botox, BTX-A, Dysport, Meditoxin and Xeomin (includes corresponding Graph/Chart).....II-9
1$350
   Botulinum Toxin Products Worldwide.....II-10
Botox – The Leading Brand in Cosmetic BTX Market.....II-10
Biosimilar BTX Variants Challenge Botox’s Leadership.....II-10
1$100
   Discontinuation of PurTox Averts Competition to Botox®.....II-11
Lack of Differentiation among Approved BTX Products.....II-11
1$100
   Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and
  Efficacy.....II-12
Revance Therapeutics: All Hopes on Topical Botox Formulation.....II-12
Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario.....II-12
1$100
   A Review of Major BTX Products.....II-13
Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of
  Approval.....II-13
1$100
   BOTOX®.....II-141$100
   Approvals and Indications of Botox in Select Regions.....II-15
Key Characteristics of Botox® and Botox® Cosmetic.....II-15
1$100
   Common Adverse Reactions with Botox.....II-16
Therapeutics to Offer Higher Prospects for Botox.....II-16
Botox Therapeutic Approvals in the US by Indication.....II-16
1$100
   Migraine Indication Bolsters Allergan’s Botox Sales.....II-17
Dysport®.....II-17
1$100
   Key Characteristics of Dysport®.....II-18
Ipsen Counts on New Indications for Future Growth of Dysport.....II-18
Dysport Therapeutic Development Pipeline by Region.....II-18
1$100
   Dysport Cosmetic Development Pipeline by Region.....II-19
Next Generation Dysport – A Breakthrough in BTX Market on the Cards.....II-19
Xeomin®.....II-19
Key Characteristics of Xeomin®.....II-19
1$100
   Xeomin® FDA Approval and Indications.....II-20
Global Expansion Helps Merz Gain in the BTX Market.....II-20
Myobloc®/NeuroBloc®.....II-20
1$100
   Key Characteristics of Myobloc®.....II-21
Meditoxin®.....II-21
PurTox®.....II-21
1$100
   Key Characteristics of PurTox®.....II-22
RT001.....II-22
Revance’s RT001 – Potential Revolution in BTX Market under Development.....II-22
How Does RT001 Work?.....II-22
1$100
   RT001 – A Potential Convenient Treatment Option for Hyperhydrosis Patients.....II-23
RT002.....II-23
RT002 – Opportunities in the Therapeutics Arena.....II-23
1$100
   Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market.....II-24
Table 4: Non-Surgical Cosmetic Procedures Worldwide (2015): Percentage Breakdown of Procedure Volume for Injectables (Botulinum Toxin, Calcium Hydroxylapatite, Hyaluronic Acid and Poly-L-Lactic Acid), Facial Rejuvenation and Others (includes corresponding Graph/Chart).....II-24
1$350
   Botulinum Toxin – The Preferred Solution in Facial Injectables Market.....II-25 1$100
   Table 5: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2015): Percentage Breakdown of Procedure Volume by Age Group (includes corresponding Graph/Chart).....II-26

Table 6: Cosmetic Botulinum Toxin Procedures Performed Worldwide (2015): Percentage Breakdown of Procedure Volume by Gender (includes corresponding Graph/Chart).....II-26
Growing Acceptance of Cosmetic BTX Treatments Favors Market Growth.....II-26
Rising Disposable Incomes Propel Sales.....II-26
1$350
   Table 7: Annual Disposable Incomes in US$ ‘000 for Select Countries (2012) (includes corresponding Graph/Chart).....II-271$350
   Longer Life Expectancy Bolsters Market Growth.....II-28
Table 8: Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart).....II-28
Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or
  Jubilation?.....II-28
1$350
   Urgent Need for Physician Education about Off-Label Usage.....II-29
High Voltage Ad Campaigns Boost Patient Awareness.....II-29
Digital Revolution to Impact Consumer Choices.....II-29
1$100
   Financing of Non-Reimbursed Healthcare: Need of the Hour.....II-30
Combination Therapies: A Double Whammy Success.....II-30
1$100
   Botulinum Toxin – Potential Applications in Treatment of Dental Diseases.....II-311$100
   Short-lived Aesthetic Effects: A Strong Business Case for Revision Treatments.....II-32
Undesirable Side Effects: A Challenge to Reckon With.....II-32
Immunogenicity Undermines Patient Compliance.....II-32
Reduction of Protein Load in BTX Products – The Probable Answer for
  Immunogenicity.....II-32
1$100
   Antigenicity: A Problematic Issue in Drug Development.....II-33
Stringent Regulations Delay Market Approvals & Put Reimbursements in Limbo.....II-33
Non-Injectable Alternatives to Turn On the Heat.....II-33
1$100
   Alternative Methods of Botulinum Application under Development – A Review.....II-34
Higher Product Costs to Challenge Market Growth.....II-34
1$100
   Consumer Skepticism: The Biggest Challenge to Beat.....II-35
Animal Cruelty – A Part & Parcel of Botox Testing.....II-35
Botulinum Toxins – A Wonder Drug or Bio-terror Threat?.....II-35
1$100
   Fears of Terrorism & Biological Warfare Thwart International Trade.....II-361$100
   Botulinum Toxin: A Poison That Cures.....II-37
Structure & Mechanism of Action.....II-37
1$100
   Disadvantages.....II-38
Classification of Botulinum Toxin.....II-38
Botulinum Toxin Type A.....II-38
1$100
   Historical Timeline of Botulinum Toxin: 1885-2002.....II-39
Botulinum Toxin Type B.....II-39
Procedure.....II-39
Anaesthesia.....II-39
1$100
   Injection Procedure.....II-40
Applications of Botulinum Toxin.....II-40
Cosmetic Applications.....II-40
Glabellar Lines.....II-40
Facial Wrinkles.....II-40
1$100
   Key Cosmetic Indications for Botulinum Toxin.....II-41
Crow's Feet.....II-41
Forehead Rhytids.....II-41
Temporal Brow Lift.....II-41
1$100
   Lower Eyelid Rhytids.....II-42
Downturned Lips.....II-42
Pebbly Chin.....II-42
Therapeutic Applications.....II-42
Movement Disorders/Pain.....II-42
Cervical Dystonia.....II-42
1$100
   Hemifacial Spasm.....II-43
Blepharospasm.....II-43
Strabismus.....II-43
1$100
   Site of Injection and Doses of Neurotoxins used in the Treatment of
  Dystonias.....II-44
1$100
   Chronic Pain.....II-45
Botox in Migraine Treatment.....II-45
1$100
   List of Countries where Botox has been Approved for Prophylaxis of Headache
  in Adults Suffering from Chronic Migraine.....II-46
Table 9: Modes of Injection of Onabotulinum ToxinA for Chronic Migraine by Dose and Muscle Injected.....II-46
Hyperhidrosis.....II-46
Bladder Dysfunctions.....II-46
1$350
   Spasticity.....II-47
Other Applications.....II-47
1$100
   Side Effects.....II-48
An Overview of Side Effects of BTX Treatment.....II-48
Table 10: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 12 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart).....II-48
1$350
   Table 11: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 44 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart).....II-491$350
   University of Kansas Researchers Study Botulinum ToxinA Role in Minimally Invasive
  Treatment of Neurogenic Bladder.....II-50
Researchers at Baylor College of Medicine Revealed Use of Botox Injections for
  Treatment of Filamentary Keratitis.....II-50
1$100
   Researchers at Medical School of Hannover and Sanford-Burnham Medical Research
  Institute Study Effect of the Hostile Human Stomach Environment on BT.....II-51
Investigators Prove Role of BTX A for Treatment of Achalasia.....II-51
1$100
   Researchers at University of Freiburg Conduct New Studies on Salmonella.....II-52
Researchers at Monash University Use Botox to Resolve Asthma Wrinkles.....II-52
1$100
   Galderma Initiates Phase II Clinical Trial on Botulinum Toxin.....II-53
Daewoong Unveils Nabota Botulinum Toxin-Type Formula.....II-53
Medy-TOX Submits Patent Application for Lyophilized Botulinum Toxin.....II-53
Botox Receives Approval for Treatment of Ankle Disability in the UK.....II-53
Anterios Develops AI-09 Next-Generation Injectable Botulinum Product.....II-53
Ipsen Receives Health Canada Approval for Dysport®.....II-53
Eisai Announces Plans to Launch Nerbloc® in Japan.....II-53
1$100
   Cangene Receives FDA Approval for Botulism Antitoxin.....II-54
Allergan Receives FDA Approval for BOTOX® for the Treatment of Crow's Feet Lines in
  Adults.....II-54
1$100
   Allergan Gains Marketing Approval for BOTOX Vista® in Japan.....II-55
Allergan Takes Over Anterios.....II-55
FDA Approves BOTOX® for Treatment of Adult Lower Limb Spasticity.....II-55
Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug
  Candidate.....II-55
Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins.....II-55
Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel.....II-55
1$100
   Revance Commences Phase 2 Study for RT002 Botulinum Toxin Type A.....II-56
Revance Begins Phase 2 Trial for Botulinum toxin Type A Topical Gel.....II-56
Bloomage BioTechnology and Medytox to Establish JV in China.....II-56
Ipsen Gains FDA’s sBLA Approval for Dysport®.....II-56
Actavis Bags FDA Approval for Expanding BOTOX® Label.....II-56
Actavis Acquires Allergan.....II-56
1$100
   Ipsen and Galderma Expand Partnership.....II-57
Allergan Completes Licensing Agreement with Medytox.....II-57
Ipsen Acquires Syntaxin.....II-57
Ipsen Enters into R&D Collaboration with Harvard Medical School.....II-57
Galderma Commences Clinical Trials on BT-based Muscle Relaxant.....II-57
Anterios Conducts Phase 2b Clinical Trials on ANT-1207 Botulinum Toxin.....II-57
Medytox Inks Technology Transfer Agreement with Allergan.....II-57
1$100
   Allergan Plc (Ireland).....II-58
Ipsen Group (France).....II-58
1$100
   Medy-Tox Inc. (South Korea).....II-59
Merz Pharma GmbH & Co. KGaA (Germany).....II-59
Metabiologics, Inc. (US).....II-59
1$100
   Revance Therapeutics, Inc. (US).....II-60
US WorldMeds (US).....II-60
1$100
   Table 12: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-611$350
   Table 13: World Historic Review for Botulinum Toxin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-621$350
   Table 14: World 14-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-631$350
   Table 15: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-641$350
   Table 16: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-651$350
   Table 17: World 14-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-661$350
   Table 18: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-671$350
   Table 19: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-681$350
   Table 20: World 14-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-691$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Therapeutic BTX Market – New Entrants Slow in Gaining Market Share.....III-1
Approved Therapeutic Indications of Botulinum Toxin in the US by Year of
  Approval.....III-1
1$75
   Neurogenic OAB – A Relatively Smaller Market Opportunity.....III-2
Idiopathic OAB Bodes Healthy Prospects for Botox.....III-2
Cosmetic BTX Market: Rapid Growth in Store.....III-2
2$150
   Table 21: Age-wise Distribution for Botulinum Toxin Procedures Performed in the US for the Year 2015 (includes corresponding Graph/Chart).....III-4

Table 22: Gender Distribution for Botulinum Toxin Procedures Performed in the US (2015) (includes corresponding Graph/Chart).....III-4
Increasing Demand for Cosmetic Treatments Bodes Well for BTX Market.....III-4
1$200
   Some Interesting Facts on Cosmetic Procedures.....III-5 1$75
   Table 23: Number of Surgical & Non-Surgical Cosmetic Procedures ('000s) in the US for the Years 1997, 2014 & 2015 (includes corresponding Graph/Chart).....III-61$200
   Table 24: Top 5 Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (In ‘000s) for 2015 (includes corresponding Graph/Chart).....III-7

Table 25: Top 5 Non-Surgical Cosmetic Procedures in the US - Ranked by the Number of Procedures Performed (‘000s) for 2015 (includes corresponding Graph/Chart).....III-7
1$200
   Table 26: Total Number of Cosmetic Procedures Performed by Category in the US (2015).....III-81$200
   Table 27: Number of Botulinum Toxin Procedures Performed in the US (1997, 2014 & 2015) (includes corresponding Graph/Chart).....III-9

Table 28: Average Cost of Botulinum Toxin Per Procedure in the US (2007- 2015) (includes corresponding Graph/Chart).....III-9
1$200
   Demand for Professional Help On Rise.....III-10
Aging Baby Boomers Drive Aesthetic Business.....III-10
Table 29: US Population by Age Group (2015 & 2030): Percentage Share Breakdown for 0-14, 15-64, and 65+ Age Groups (includes corresponding Graph/Chart).....III-10
1$200
   Table 30: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-11
Expanding Physician Base Extends Impetus to Growth.....III-11
1$200
   Table 31: Average Physician/Surgeon Fees per Procedure in the US (2015).....III-121$200
   Competitive Landscape.....III-13
Allergan’s Botox Leads Cosmetic BTX Market.....III-13
Major BTX Products and Associated Fillers in the Cosmetic Botulinum Toxin
  Market.....III-13
Table 32: Leading Brands in the US Cosmetic Neurotoxin Treatment Market (2015): Percentage Breakdown of Value Sales for Botox, Dysport and Others (includes corresponding Graph/Chart).....III-13
1$200
   Dysport Takes on Botox in the Therapeutic Space.....III-14
Table 33: Leading Brands in the US Therapeutic Botulinum Toxin Market (2013): Percentage Breakdown of Value Sales for Botox and Dysport (includes corresponding Graph/Chart).....III-14
AAN Releases New Guidelines on BTX for Identified Disorders.....III-14
1$200
   Rise in Botulinum Toxin Lawsuits – A Concern for Physicians?.....III-151$75
   Product Launches/Approvals.....III-16
Strategic Corporate Developments.....III-16
2$150
   Key Players.....III-181$75
   B. Market Analytics.....III-19
Table 34: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-19
1$200
   Table 35: US Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-201$200
   Table 36: US 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-211$200
   Market Analysis.....III-22
Table 37: Canadian Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-22
1$200
   Table 38: Canadian Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-231$200
   Table 39: Canadian 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Current and Future Analysis.....III-25
Strategic Corporate Development.....III-25
1$75
   B. Market Analytics.....III-26
Table 40: Japanese Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-26
1$200
   Table 41: Japanese Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-271$200
   Table 42: Japanese 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
Current and Future Analysis.....III-29
BTX Cosmetic Market Positioned for Growth.....III-29
Botox Approvals and Indications in Select European Countries.....III-29
1$75
   Anti-Aging Treatment on the Rise among Young Mothers.....III-30
Regulations for Botulinum Toxin Usage in the EU.....III-30
The United Kingdom.....III-30
Cosmetic Treatment Procedures in the UK.....III-30
1$75
   Snapshots.....III-311$75
   Russia.....III-32
Mandates Registration of BTX Drugs.....III-32
Product Approvals/Trials.....III-32
1$75
   Strategic Corporate Developments.....III-331$75
   Key Players.....III-342$150
   B. Market Analytics.....III-36
Table 43: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-36
1$200
   Table 44: European Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-371$200
   Table 45: European 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-381$200
   A. Market Analysis.....III-39
Current and Future Analysis.....III-39
Botox Approvals and Indications in Select Asian Countries.....III-39
A Peek into Select Markets.....III-39
Australia.....III-39
1$75
   China.....III-40
Rising Demand for Cosmetic Treatments – Opportunity for BTX.....III-40
Botulinum Toxin Injections Approved by China Food and Drug Administration
  (CFDA).....III-40
India – An Emerging Market for Botox.....III-40
1$75
   South Korea.....III-41
Botulinum Toxin Market – Cosmetic Sector to Fuel Growth.....III-41
Table 46: South Korean Botulinum Toxin Use by Application for the Years 2005, 2010 and 2015 (includes corresponding Graph/Chart).....III-41
Strong Demand for Cosmetic Procedures – Potential for BTX Market.....III-41
1$200
   Table 47: Working Women as % of Total Female Population and Monthly Income of Working Women (in KRW Million) for 2005, 2010 & 2015 (includes corresponding Graph/Chart).....III-42

Table 48: Aging Population in Korea (2015 & 2025): Percentage Breakdown of Population by Age Group (includes corresponding Graph/Chart).....III-42
1$200
   Table 49: Foreign Patients Visiting Korea for Plastic Surgery & Dermatology Procedures as a % of Total Visits of Foreign Patients (includes corresponding Graph/Chart).....III-43
Meditoxin Dominates Domestic BTX Market.....III-43
1$200
   Table 50: Leading Brands in the South Korean Botulinum Toxin Market (2015): Percentage Breakdown of Sales for Botox, Botulax, Meditoxin, Nabota and Others (includes corresponding Graph/Chart).....III-44

Table 51: Average Price of Botulinum Toxin Products by Brand in South Korea (2015) (In KRW per Unit) (includes corresponding Graph/Chart).....III-44
1$200
   List of Domestic Botox Products in Korea.....III-45
Product Launches/Approvals.....III-45
1$75
   Strategic Corporate Developments.....III-46
Key Players.....III-46
2$150
   B. Market Analytics.....III-48
Table 52: Asia-Pacific Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-48
1$200
   Table 53: Asia-Pacific Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-491$200
   Table 54: Asia-Pacific 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-501$200
   A. Market Analysis.....III-51
Current and Future Analysis.....III-51
Latin America: Facial Injectables Market Set for Strong Growth.....III-51
Israel: Health Ministry Bans Cosmetic Botox Treatment by Dentists.....III-51
1$75
   Botox Approvals and Indications in RoW.....III-52
Botox Approvals and Indications in Select Latin American Regions.....III-52
Botox Approvals and Indications in Other Select Global Regions.....III-52
1$75
   B. Market Analytics.....III-53
Table 55: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-53
1$200
   Table 56: Rest of World Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-541$200
   Table 57: Rest of World 14-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic and Therapeutic Markets for the Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-551$200
  
Total Companies Profiled: 15 (including Divisions/Subsidiaries - 18)

Region/Country Players

The United States 6 Japan 1 Europe 5 France 1 Germany 1 The United Kingdom 1 Rest of Europe 2 Asia-Pacific (Excluding Japan) 6
Click here to request a full table of contents and more details on this project.